WBR1122

Jump to navigation Jump to search
 
Author [[PageAuthor::Mohamed Moubarak, M.D. [1]]]
Exam Type ExamType::USMLE Step 3
Main Category MainCategory::Primary Care Office
Sub Category SubCategory::Endocrine, SubCategory::Endocrine
Prompt [[Prompt::A 45 year-old female comes to your office for follow up after being diagnosed with type 2 diabetes mellitus 1 month ago. She has been following a diet and exercise to control her hyperglycemic state without medication, but so far it has no effect on her blood glucose level. Her recent laboratory test results are shown below:
  • Hemoglobin 13 mg/dL
  • Total blood cholesterol of 270mg/dL
  • LDL of 190mg/dL
  • HDL of 28 mg/dL
  • Glucose 190 mg/dL
  • HgbA1C 9.8%
  • BUN 35
  • Creatinine 3.4
  • eGFR <30 mL/min
  • ALT 15 IU/L
  • AST 10 IU/L

You decided to start a medical therapy to control her hyperglycemia. Which of the following is the best initial medical therapy for her condition?]]

Answer A AnswerA::Metformin
Answer A Explanation [[AnswerAExp::Incorrect

Metformin is contraindicated in those with renal dysfunction.]]

Answer B AnswerB::Sulfonylureas
Answer B Explanation [[AnswerBExp::Correct

Sulfonylureas are the oral hypoglycemic drug of choice in patients with renal dysfunction.]]

Answer C AnswerC::Glitazones
Answer C Explanation [[AnswerCExp::Incorrect

Short acting sulfonylureas are the oral hypoglycemic drug of choice in patients with renal dysfunction.]]

Answer D AnswerD::Insulin
Answer D Explanation [[AnswerDExp::Incorrect

If oral hypoglycemic drugs fail (or stop helping), insulin therapy may be necessary, usually in addition to oral medication therapy, to maintain normal glucose levels.]]

Answer E AnswerE::Alpha glucosidase inhibitors
Answer E Explanation [[AnswerEExp::Incorrect

Short acting sulfonylureas are the oral hypoglycemic drug of choice in patients with renal dysfunction.]]

Right Answer RightAnswer::B
Explanation [[Explanation::Metformin is contraindicated in those with renal dysfunction because it can accumulate and cause metabolic acidosis. It should not be used among chronic kidney disease(CKD) patients with eGFR <30 mL/min because of an increased risk of lactic acidosis. The 2012 Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommended that metformin may be used among patients with an estimated GFR >45 mL/min.

The oral agents that are thought to be relatively safe in patients with non-dialysis CKD include short-acting sulfonylureas (eg, glipizide) and repaglinide.
Educational Objective: Metformin is contraindicated in those with renal dysfunction, the oral agents that are thought to be relatively safe in patients with non-dialysis CKD include short-acting sulfonylureas (eg, glipizide) and repaglinide.
References: The 2012 Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines.]]

Approved Approved::No
Keyword [[WBRKeyword::Diabetes mellitus type 2]]
Linked Question Linked::
Order in Linked Questions LinkedOrder::